Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 2.06
EGRX's Cash-to-Debt is ranked higher than
51% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. EGRX: 2.06 )
Ranked among companies with meaningful Cash-to-Debt only.
EGRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.77  Med: No Debt Max: No Debt
Current: 2.06
0.77
No Debt
Equity-to-Asset 0.72
EGRX's Equity-to-Asset is ranked higher than
58% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. EGRX: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
EGRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.86  Med: 0.72 Max: 0.8
Current: 0.72
-4.86
0.8
Debt-to-Equity 0.23
EGRX's Debt-to-Equity is ranked higher than
57% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. EGRX: 0.23 )
Ranked among companies with meaningful Debt-to-Equity only.
EGRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09  Med: 0.26 Max: 0.29
Current: 0.23
-0.09
0.29
Debt-to-EBITDA 1.26
EGRX's Debt-to-EBITDA is ranked higher than
64% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. EGRX: 1.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EGRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43  Med: 0.09 Max: 1.26
Current: 1.26
-0.43
1.26
Interest Coverage 15.26
EGRX's Interest Coverage is ranked lower than
63% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. EGRX: 15.26 )
Ranked among companies with meaningful Interest Coverage only.
EGRX' s Interest Coverage Range Over the Past 10 Years
Min: 15.26  Med: 232.73 Max: 6569.75
Current: 15.26
15.26
6569.75
Piotroski F-Score: 6
Altman Z-Score: 7.06
Beneish M-Score: -2.36
WACC vs ROIC
13.05%
31.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 19.90
EGRX's Operating Margin % is ranked higher than
85% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. EGRX: 19.90 )
Ranked among companies with meaningful Operating Margin % only.
EGRX' s Operating Margin % Range Over the Past 10 Years
Min: -781.06  Med: -28.97 Max: 31.9
Current: 19.9
-781.06
31.9
Net Margin % 13.92
EGRX's Net Margin % is ranked higher than
76% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. EGRX: 13.92 )
Ranked among companies with meaningful Net Margin % only.
EGRX' s Net Margin % Range Over the Past 10 Years
Min: -763.41  Med: -20.17 Max: 42.99
Current: 13.92
-763.41
42.99
ROE % 15.64
EGRX's ROE % is ranked higher than
81% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. EGRX: 15.64 )
Ranked among companies with meaningful ROE % only.
EGRX' s ROE % Range Over the Past 10 Years
Min: 4.17  Med: 31.45 Max: 67.44
Current: 15.64
4.17
67.44
ROA % 10.68
EGRX's ROA % is ranked higher than
84% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. EGRX: 10.68 )
Ranked among companies with meaningful ROA % only.
EGRX' s ROA % Range Over the Past 10 Years
Min: -205.37  Med: -20.52 Max: 48.07
Current: 10.68
-205.37
48.07
ROC (Joel Greenblatt) % 52.97
EGRX's ROC (Joel Greenblatt) % is ranked higher than
93% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. EGRX: 52.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EGRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5164.61  Med: -715.82 Max: 359.13
Current: 52.97
-5164.61
359.13
3-Year Revenue Growth Rate 98.00
EGRX's 3-Year Revenue Growth Rate is ranked higher than
98% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. EGRX: 98.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EGRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 37  Med: 38.4 Max: 98
Current: 98
37
98
GuruFocus has detected 2 Warning Signs with Eagle Pharmaceuticals Inc EGRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EGRX's 30-Y Financials

Financials (Next Earnings Date: 2019-02-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

EGRX Guru Trades in

Q1 2018

EGRX Guru Trades in Q1 2018

Charles Brandes 25,219 sh (New)
Ken Fisher 29,784 sh (unchged)
First Eagle Investment 500,922 sh (-16.72%)
Joel Greenblatt 17,044 sh (-67.37%)
Chuck Royce 70,043 sh (-23.31%)
» More
Q2 2018

EGRX Guru Trades in Q2 2018

Paul Tudor Jones 4,033 sh (New)
Ken Fisher 20,752 sh (-30.33%)
First Eagle Investment 226,333 sh (-54.82%)
Joel Greenblatt 14,369 sh (-15.69%)
Charles Brandes 11,985 sh (-52.48%)
Chuck Royce 40,275 sh (-42.50%)
» More
Q3 2018

EGRX Guru Trades in Q3 2018

John Hussman 25,000 sh (New)
Pioneer Investments 23,200 sh (New)
Chuck Royce 41,033 sh (+1.88%)
Paul Tudor Jones 12,577 sh (+211.85%)
Ken Fisher 17,925 sh (-13.62%)
Charles Brandes 3,658 sh (-69.48%)
First Eagle Investment 213,822 sh (-5.53%)
Joel Greenblatt 10,203 sh (-28.99%)
» More
» Details

Insider Trades

Latest Guru Trades with EGRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:002864, BOM:540222, SHSE:603669, NAS:OPTN, NAS:ADMS, SZSE:002365, NAS:COLL, XKRX:243070, ISX:SIDO, SZSE:300584, SZSE:002880, HKSE:00950, SZSE:300683, XKRX:001060, OSTO:BIOG B, SZSE:000597, NAS:KPTI, TPE:1789, NSE:STAR, SHSE:600530 » details
Traded in other countries:1E6.Germany,
Headquarter Location:USA
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, docetaxel injection, non-alcohol formulation and Bendeka. The company currently have multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

Guru Investment Theses on Eagle Pharmaceuticals Inc

First Eagle Fund of America Comments on Eagle Pharmaceuticals - Oct 31, 2017

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) fell after the FDA denied approval for the company’s lead drug, Ryanodex, for a new indication—exertional heat stroke (EHS). The drug is currently marketed for malignant hypothermia, and the company continues to conduct trials for other indications while holding further discussions with the FDA about the drug’s potential for EHS. The market appears to ascribe little value to any future indications, but we see the potential for upside if any are approved.



From First Eagle Fund of America third quarter 2017 shareholder commentary.



Check out First Eagle Investment latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 24.13
EGRX's PE Ratio is ranked lower than
75% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. EGRX: 24.13 )
Ranked among companies with meaningful PE Ratio only.
EGRX' s PE Ratio Range Over the Past 10 Years
Min: 8.06  Med: 26.35 Max: 462.71
Current: 24.13
8.06
462.71
Forward PE Ratio 9.33
EGRX's Forward PE Ratio is ranked higher than
70% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. EGRX: 9.33 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.13
EGRX's PE Ratio without NRI is ranked lower than
74% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. EGRX: 24.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
EGRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.06  Med: 26.35 Max: 462.71
Current: 24.13
8.06
462.71
Price-to-Owner-Earnings 64.16
EGRX's Price-to-Owner-Earnings is ranked lower than
86% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. EGRX: 64.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EGRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.64  Med: 23.73 Max: 100.19
Current: 64.16
8.64
100.19
PB Ratio 3.41
EGRX's PB Ratio is ranked lower than
82% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. EGRX: 3.41 )
Ranked among companies with meaningful PB Ratio only.
EGRX' s PB Ratio Range Over the Past 10 Years
Min: 2.82  Med: 6.53 Max: 17.1
Current: 3.41
2.82
17.1
PS Ratio 3.37
EGRX's PS Ratio is ranked lower than
70% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. EGRX: 3.37 )
Ranked among companies with meaningful PS Ratio only.
EGRX' s PS Ratio Range Over the Past 10 Years
Min: 1.69  Med: 5.71 Max: 28.43
Current: 3.37
1.69
28.43
Price-to-Free-Cash-Flow 18.44
EGRX's Price-to-Free-Cash-Flow is ranked higher than
50% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. EGRX: 18.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EGRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.49  Med: 21.36 Max: 232.79
Current: 18.44
11.49
232.79
Price-to-Operating-Cash-Flow 17.17
EGRX's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. EGRX: 17.17 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EGRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.96  Med: 19.75 Max: 229.12
Current: 17.17
9.96
229.12
EV-to-EBIT 18.16
EGRX's EV-to-EBIT is ranked lower than
75% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. EGRX: 18.16 )
Ranked among companies with meaningful EV-to-EBIT only.
EGRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -358.9  Med: 14.4 Max: 650.1
Current: 18.16
-358.9
650.1
EV-to-EBITDA 16.20
EGRX's EV-to-EBITDA is ranked lower than
79% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. EGRX: 16.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
EGRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -364.3  Med: 14.1 Max: 621.6
Current: 16.2
-364.3
621.6
EV-to-Revenue 2.79
EGRX's EV-to-Revenue is ranked lower than
66% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. EGRX: 2.79 )
Ranked among companies with meaningful EV-to-Revenue only.
EGRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 6.2 Max: 27.6
Current: 2.79
1.4
27.6
Current Ratio 5.58
EGRX's Current Ratio is ranked higher than
72% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. EGRX: 5.58 )
Ranked among companies with meaningful Current Ratio only.
EGRX' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.56 Max: 5.87
Current: 5.58
0.42
5.87
Quick Ratio 5.38
EGRX's Quick Ratio is ranked higher than
75% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. EGRX: 5.38 )
Ranked among companies with meaningful Quick Ratio only.
EGRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.43 Max: 5.66
Current: 5.38
0.42
5.66
Days Inventory 38.19
EGRX's Days Inventory is ranked higher than
90% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. EGRX: 38.19 )
Ranked among companies with meaningful Days Inventory only.
EGRX' s Days Inventory Range Over the Past 10 Years
Min: 2.15  Med: 22.62 Max: 190.54
Current: 38.19
2.15
190.54
Days Sales Outstanding 140.35
EGRX's Days Sales Outstanding is ranked lower than
75% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. EGRX: 140.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.28  Med: 138.08 Max: 227.28
Current: 140.35
81.28
227.28
Days Payable 48.25
EGRX's Days Payable is ranked higher than
69% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. EGRX: 48.25 )
Ranked among companies with meaningful Days Payable only.
EGRX' s Days Payable Range Over the Past 10 Years
Min: 48.25  Med: 93.55 Max: 166.48
Current: 48.25
48.25
166.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.90
EGRX's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. EGRX: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EGRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.5  Med: -3.2 Max: -1.9
Current: -1.9
-111.5
-1.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 40.00
EGRX's Price-to-Net-Cash is ranked lower than
91% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. EGRX: 40.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EGRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.02  Med: 18.79 Max: 1972.25
Current: 40
5.02
1972.25
Price-to-Net-Current-Asset-Value 5.38
EGRX's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. EGRX: 5.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EGRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.03  Med: 8.4 Max: 26.45
Current: 5.38
4.03
26.45
Price-to-Tangible-Book 4.88
EGRX's Price-to-Tangible-Book is ranked lower than
85% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. EGRX: 4.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EGRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4  Med: 7.8 Max: 15.56
Current: 4.88
4
15.56
Price-to-Intrinsic-Value-Projected-FCF 2.16
EGRX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. EGRX: 2.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EGRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.16  Med: 4.05 Max: 4.72
Current: 2.16
2.16
4.72
Price-to-Median-PS-Value 0.59
EGRX's Price-to-Median-PS-Value is ranked higher than
51% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. EGRX: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EGRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1 Max: 4.17
Current: 0.59
0.4
4.17
Price-to-Graham-Number 2.29
EGRX's Price-to-Graham-Number is ranked lower than
86% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. EGRX: 2.29 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EGRX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.86  Med: 2.79 Max: 16.99
Current: 2.29
1.86
16.99
Earnings Yield (Greenblatt) % 5.51
EGRX's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. EGRX: 5.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EGRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -21.2  Med: 0.6 Max: 12
Current: 5.51
-21.2
12

More Statistics

Revenue (TTM) (Mil) $204.04
EPS (TTM) $ 1.84
Beta1.77
Volatility53.87%
52-Week Range $36.03 - 85.66
Shares Outstanding (Mil)13.90

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 3.99 4.76
EPS without NRI ($) 3.99 4.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}